{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T21:26:07Z","timestamp":1792790767215,"version":"4.5.0"},"reference-count":73,"publisher":"Wiley","issue":"2","license":[{"start":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T00:00:00Z","timestamp":1761004800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"funder":[{"DOI":"10.13039\/100004325","name":"AstraZeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["European J of Haematology"],"published-print":{"date-parts":[[2026,2]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background\/Objectives<\/jats:title>\n                    <jats:p>Bruton tyrosine kinase inhibitors (BTKis) have revolutionized treatment for chronic lymphocytic leukemia (CLL), but cardiovascular (CV) toxicities pose significant challenges. Second\u2010generation BTKis offer improved target specificity, yet CV risks persist. This expert opinion review evaluates current evidence and offers guidance for managing BTKi\u2010associated CV events, particularly in patients with comorbidities.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>A hematologist, specialist in CLL, and a cardiologist with specific expertise in managing cardiac complications arising from oncologic therapies conducted a systematic literature review. Subsequently, clinical findings synthesized through multidisciplinary expert discussions led to the development of practical recommendations for CV risk stratification and management in patients with CLL receiving BTKi therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Regular CV monitoring is essential for early detection of atrial fibrillation (AF), hypertension, and ventricular arrhythmias. A multidisciplinary approach between hematologists and cardiologists is recommended for comprehensive care. Identifying hematological biomarkers for predicting cardiotoxicity and exploring cardioprotective therapies for high\u2010risk patients should be prioritized.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>It is essential to educate healthcare providers about the CV risks associated with BTKis. Additionally, clinical guidelines should be regularly updated to reflect the latest evidence, ensuring effective prevention and management strategies. In patients with a heightened risk of CV complications, the use of second\u2010generation BTKis should be prioritized. Ongoing cardiovascular monitoring is also recommended to reduce the risk of adverse events and minimize treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1111\/ejh.70047","type":"journal-article","created":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T08:02:36Z","timestamp":1761033756000},"page":"104-115","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":10,"title":["Cardiovascular Challenges in Chronic Lymphocytic Leukemia (\n                    <scp>CLL<\/scp>\n                    ) Patients Undergoing Bruton Tyrosine Kinase (\n                    <scp>BTK<\/scp>\n                    ) Inhibitor Therapy"],"prefix":"10.1111","volume":"116","author":[{"given":"Stefano","family":"Oliva","sequence":"first","affiliation":[{"name":"Cardio\u2010Oncology Unit IRCCS Istituto Tumori, \u201cGiovanni Paolo II\u201d  Bari Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2795-6507","authenticated-orcid":false,"given":"Stefano","family":"Molica","sequence":"additional","affiliation":[{"name":"Department of Hematology Hull University Teaching Hospitals NHS Trust  Hull UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2025,10,21]]},"reference":[{"key":"e_1_2_19_2_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2023.09.002"},{"key":"e_1_2_19_3_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2019000840"},{"key":"e_1_2_19_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.638"},{"key":"e_1_2_19_5_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.01210"},{"key":"e_1_2_19_6_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2211582"},{"key":"e_1_2_19_7_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2022007938"},{"key":"e_1_2_19_8_1","doi-asserted-by":"publisher","DOI":"10.1002\/hon.2503"},{"key":"e_1_2_19_9_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.critrevonc.2024.104428"},{"key":"e_1_2_19_10_1","doi-asserted-by":"publisher","DOI":"10.1136\/openhrt-2019-001049"},{"key":"e_1_2_19_11_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacep.2018.06.004"},{"key":"e_1_2_19_12_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2014-10-604272"},{"key":"e_1_2_19_13_1","doi-asserted-by":"publisher","DOI":"10.2353\/ajpath.2009.090126"},{"key":"e_1_2_19_14_1","doi-asserted-by":"publisher","DOI":"10.1007\/s10637-019-00837-w"},{"key":"e_1_2_19_15_1","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-15-0741"},{"key":"e_1_2_19_16_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cjca.2017.12.001"},{"key":"e_1_2_19_17_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.049210"},{"key":"e_1_2_19_18_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jscai.2023.100608"},{"key":"e_1_2_19_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.blre.2025.101268"},{"key":"e_1_2_19_20_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.14785"},{"key":"e_1_2_19_21_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15174391"},{"key":"e_1_2_19_22_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2021005716"},{"key":"e_1_2_19_23_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-20-3993"},{"key":"e_1_2_19_24_1","doi-asserted-by":"publisher","DOI":"10.1080\/17474086.2024.2366534"},{"key":"e_1_2_19_25_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2017009720"},{"key":"e_1_2_19_26_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118"},{"key":"e_1_2_19_27_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2024.06.016"},{"key":"e_1_2_19_28_1","doi-asserted-by":"publisher","DOI":"10.6004\/jnccn.2024.0018"},{"key":"e_1_2_19_29_1","article-title":"Prediction Models for Cardiovascular Disease Risk in the General Population: Systematic Review","volume":"353","author":"Damen J. A.","year":"2016","journal-title":"BMJ (Clinical Research Ed.)"},{"issue":"25","key":"e_1_2_19_30_1","first-page":"S74","article-title":"American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. 2013 ACC\/AHA Guideline on the Assessment of Cardiovascular Risk: A Report of the American College of Cardiology\/American Heart Association Task Force on Practice Guidelines. Circulation. 2014;129(25 Suppl 2):S49\u201373. Epub 2013 Nov 12. Erratum","volume":"129","author":"Goff D. C.","year":"2014","journal-title":"Circulation"},{"key":"e_1_2_19_31_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.b2584"},{"key":"e_1_2_19_32_1","doi-asserted-by":"publisher","DOI":"10.2147\/VHRM.S404575"},{"key":"e_1_2_19_33_1","doi-asserted-by":"publisher","DOI":"10.1080\/08977194.2021.1932870"},{"key":"e_1_2_19_34_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2016.1257795"},{"key":"e_1_2_19_35_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jaccao.2024.02.006"},{"key":"e_1_2_19_36_1","doi-asserted-by":"publisher","DOI":"10.3322\/caac.21763"},{"key":"e_1_2_19_37_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.12145"},{"key":"e_1_2_19_38_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2024-199765"},{"key":"e_1_2_19_39_1","doi-asserted-by":"publisher","DOI":"10.1182\/bloodadvances.2023012142"},{"key":"e_1_2_19_40_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-024-02334-3"},{"key":"e_1_2_19_41_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.2024.42.16_suppl.e19030"},{"key":"e_1_2_19_42_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2016-10-742437"},{"key":"e_1_2_19_43_1","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(23)00144-4"},{"key":"e_1_2_19_44_1","doi-asserted-by":"publisher","DOI":"10.1111\/bjh.19469"},{"key":"e_1_2_19_45_1","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2019.16326"},{"key":"e_1_2_19_46_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0211228"},{"key":"e_1_2_19_47_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_2_19_48_1","doi-asserted-by":"publisher","DOI":"10.3389\/fcell.2021.630942"},{"issue":"3","key":"e_1_2_19_49_1","first-page":"744","article-title":"Cumulative Review of Hypertension in Patients With Chronic Lymphocytic Leukemia Treated With Acalabrutinib","volume":"110","author":"Ferrajoli A.","year":"2025","journal-title":"Haematologica"},{"key":"e_1_2_19_50_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2019.07.056"},{"key":"e_1_2_19_51_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.21.00693"},{"key":"e_1_2_19_52_1","doi-asserted-by":"publisher","DOI":"10.3324\/haematol.2021.278901"},{"issue":"1","key":"e_1_2_19_53_1","first-page":"92","article-title":"Pirtobrutinib Monotherapy in Bruton Tyrosine Kinase Inhibitor\u2010Intolerant Patients With B\u2010Cell Malignancies: Results of the Phase I\/II BRUIN Trial","volume":"110","author":"Shah N. N.","year":"2025","journal-title":"Haematologica"},{"key":"e_1_2_19_54_1","doi-asserted-by":"publisher","DOI":"10.1002\/ajh.27544"},{"key":"e_1_2_19_55_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2300696"},{"key":"e_1_2_19_56_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood-2022-157589"},{"key":"e_1_2_19_57_1","doi-asserted-by":"publisher","DOI":"10.1200\/JCO-25-00166"},{"key":"e_1_2_19_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bneo.2024.100034"},{"key":"e_1_2_19_59_1","doi-asserted-by":"publisher","DOI":"10.1056\/EVIDoa2200006"},{"key":"e_1_2_19_60_1","doi-asserted-by":"publisher","DOI":"10.1158\/1078-0432.CCR-22-2779"},{"key":"e_1_2_19_61_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2021014488"},{"key":"e_1_2_19_62_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2310063"},{"key":"e_1_2_19_63_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2409804"},{"issue":"4","key":"e_1_2_19_64_1","article-title":"AMPLIFY: A Second\u2010Generation BTK Inhibitor for Fixed\u2010Duration Therapy in Chronic Lymphocytic Leukemia","volume":"6","author":"Molica S.","year":"2025","journal-title":"Medicus"},{"key":"e_1_2_19_65_1","doi-asserted-by":"publisher","DOI":"10.3390\/ijms23116260"},{"key":"e_1_2_19_66_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2024024631"},{"issue":"7","key":"e_1_2_19_67_1","article-title":"First\u2010Line Venetoclax Combinations Versus Chemoimmunotherapy in Fit Patients With Chronic Lymphocytic Leukaemia (GAIA\/CLL13): 4\u2010Year Follow\u2010Up From a Multicentre, Open\u2010Label, Randomised, Phase 3 Trial","volume":"25","author":"F\u00fcrstenau M.","year":"2024","journal-title":"Lancet Oncology"},{"key":"e_1_2_19_68_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehad196"},{"key":"e_1_2_19_69_1","doi-asserted-by":"publisher","DOI":"10.1111\/echo.14946"},{"key":"e_1_2_19_70_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215637"},{"key":"e_1_2_19_71_1","doi-asserted-by":"publisher","DOI":"10.1186\/s13045-022-01302-7"},{"key":"e_1_2_19_72_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2021.12.012"},{"issue":"7","key":"e_1_2_19_73_1","article-title":"Realizing Precision Medicine in Chronic Lymphocytic Leukemia: Remaining Challenges and Potential Opportunities","volume":"8","author":"Stamatopoulos K.","year":"2024","journal-title":"Hema"},{"key":"e_1_2_19_74_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2022016953"}],"container-title":["European Journal of Haematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/ejh.70047","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T12:10:16Z","timestamp":1767874216000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/ejh.70047"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,21]]},"references-count":73,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2026,2]]}},"alternative-id":["10.1111\/ejh.70047"],"URL":"https:\/\/doi.org\/10.1111\/ejh.70047","archive":["Portico"],"relation":{},"ISSN":["0902-4441","1600-0609"],"issn-type":[{"value":"0902-4441","type":"print"},{"value":"1600-0609","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,21]]},"assertion":[{"value":"2025-07-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-09-26","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-10-21","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}